Hexacath was founded in 1994 as an independent company for the development, production and distribution of innovative products for the treatment of vascular pathologies.

Since 1996, Hexacath has led an ambitious program of research and development of cooperation with state laboratories and leaders of public opinion from different countries, with the aim of creating a single line of advanced cardiovascular products. Over the past 10 years, huge investments have been made to develop a unique patented stent technology with bioactive coating (BAS) based on titanium oxynitride (TiNO), which represents a real alternative to drug-coated (DES) and holometallic stents, allowing to reduce the risk of stenosis and thrombosis in patients in the long term.

In 2011, Hexacath launched a line of innovative bio-active stents (BAS) for the treatment of peripheral arteries (superficial femoral, popliteal, iliac, renal arteries). Clinical trials of coronary BAS versus DES, a recognized gold standard for drug-eluting stents, have also been performed. Based on the results of clinical trials, the compatibility of BAS with DES of the last generation and their complete superiority over DES of the first generation was confirmed.

Hexacath is certified, and all products sold are CE marked. The company's production facilities are located in France, on the border with Switzerland. This area is famous for its experience in the fields of micromechanics and know-how in working with metals for several centuries, and could be proudly named the "European Silicon Valley". Since 1999, Hexacath products have been distributed through an extensive network of branches (Italy-Spain-France-Belgium-Finland-Latin America-China-India-and so on), and through exclusive distributors in more than 40 countries.

Hexacath products are presented in the Daksmed Group of Companies portfolio in the following areas: Coronary angioplasty and Peripheral Angioplasty